ProShare Advisors LLC Invests $249,000 in Celcuity, Inc. $CELC

ProShare Advisors LLC bought a new position in Celcuity, Inc. (NASDAQ:CELC) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 5,046 shares of the company’s stock, valued at approximately $249,000.

Other large investors have also bought and sold shares of the company. New York State Common Retirement Fund raised its position in Celcuity by 68.0% in the 3rd quarter. New York State Common Retirement Fund now owns 47,704 shares of the company’s stock valued at $2,357,000 after purchasing an additional 19,313 shares during the last quarter. Atle Fund Management AB acquired a new stake in shares of Celcuity in the third quarter valued at $1,836,000. Candriam S.C.A. increased its stake in shares of Celcuity by 48.3% in the third quarter. Candriam S.C.A. now owns 390,924 shares of the company’s stock valued at $19,312,000 after buying an additional 127,348 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Celcuity by 2,142.0% in the third quarter. Nisa Investment Advisors LLC now owns 15,627 shares of the company’s stock valued at $772,000 after buying an additional 14,930 shares during the last quarter. Finally, Saturn V Capital Management LP lifted its position in Celcuity by 8.4% during the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock worth $15,827,000 after buying an additional 91,843 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on CELC shares. Wells Fargo & Company began coverage on shares of Celcuity in a research report on Friday, December 12th. They issued an “overweight” rating and a $126.00 price objective for the company. Craig Hallum increased their price target on shares of Celcuity from $96.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Celcuity in a research report on Wednesday, January 21st. Wall Street Zen downgraded Celcuity from a “hold” rating to a “sell” rating in a report on Sunday, October 26th. Finally, Jefferies Financial Group increased their price objective on Celcuity from $108.00 to $134.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $105.25.

Insider Activity

In other Celcuity news, Director David Dalvey sold 20,000 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total transaction of $2,400,600.00. Following the transaction, the director owned 90,000 shares in the company, valued at approximately $10,802,700. This trade represents a 18.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard E. Buller sold 3,000 shares of the business’s stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $105.69, for a total value of $317,070.00. Following the transaction, the director owned 6,760 shares of the company’s stock, valued at $714,464.40. The trade was a 30.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 15.78% of the company’s stock.

Celcuity Price Performance

CELC opened at $104.79 on Monday. The company has a fifty day moving average price of $105.68 and a two-hundred day moving average price of $80.82. The firm has a market capitalization of $4.85 billion, a PE ratio of -28.55 and a beta of 0.36. Celcuity, Inc. has a 52 week low of $7.57 and a 52 week high of $120.32. The company has a debt-to-equity ratio of 2.74, a quick ratio of 12.26 and a current ratio of 12.26.

Celcuity Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.